Wyeth-Ayerst Cordarone I.V. approved Aug. 3 for life-threatening arrhythmias in refractory patients.
WYETH-AYERST CORDARONE INJECTION APPROVED AUG. 3 following two "approvable" phases. Cordarone (amiodarone) is indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. A controlled study of the class III antiarrhythmic drug showed that a rapid onset regimen of Cordarone I.V. followed by maintenance infusion reduced episodes of VT "by 85% compared to baseline," labeling states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth